Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUMINA-1: Garetosmab in FOP
NCT03188666Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Feb 2018
- Primary completion
- Sep 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 2 trial of garetosmab in fibrodysplasia ossificans progressiva (FOP), sponsored by Regeneron Pharmaceuticals. Started Feb 2018; status: completed.
02
Drugs
garetosmab
03
Conditions
fibrodysplasia ossificans progressiva (FOP)
Beyond the preview
Go deeper on NCT03188666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03188666.